ribociclib (as succinate) film coated tablets
Consumer Medicine Information
What is in this leaflet
Please read this leaflet carefully before you start using KISQALI.
This leaflet answers some common questions about KISQALI.
It does not contain all the available information. It does not take the place of talking
to your doctor or pharmacist.
The information in this leaflet was last updated on the date listed on the final page.
More recent information on the medicine may be available.
You should ensure that you speak to your pharmacist or doctor to obtain the most up
to date information on the medicine.
You can also download the most up to date leaflet from www.novartis.com.au or from
Those updates may contain important information about the medicine and its use of
which you should be aware.
All medicines have risks and benefits. Your doctor has weighed the risks of you taking
KISQALI against the benefits they expect it will have for you.
If you have any concerns about taking this medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine.
You may need to read it again.
What KISQALI is used for
KISQALI tablet contains an active substance called ribociclib. It is used to treat
hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-
negative breast cancer that is locally advanced or may have also spread to other parts
of the body (metastatic).
KISQALI is used in combination with a second medicine (either an aromatase inhibitor
or fulvestrant), which are used as hormonal anticancer therapies.
If KISQALI is used in women who have not reached menopause in combination with an
aromatase inhibitor, a third medicine must also be used from the group of luteinising
hormone-releasing hormone (LHRH) agonists. This medicine controls the function of
your ovaries, by reducing the amount of oestrogen (a hormone) that is produced by
KISQALI is believed to work by blocking the effects of types of enzymes, called cyclin
dependent kinases (CDK) that chemically signal cancer cells to grow and multiply.
By blocking these enzymes, KISQALI may delay the growth of breast cancer cells.
Ask your doctor or pharmacist if you have any questions about why this medicine has
been prescribed for you.
Your doctor may have prescribed KISQALI for another reason.
This medicine should not be used in children and adolescents, under the age of 18
This medicine is available only with a doctor's prescription. It is not addictive.
Please also read the Consumer Medicine Information (CMI) for the other medicines used
in combination with KISQALI carefully as well. That is, the:
Aromatase inhibitor OR fulvestrant, depending on what your doctor has prescribed.
LHRH agonist (if you are a premenopausal or perimenopausal woman).
Before you take KISQALI
When you must not use it
Do not take KISQALI if you have an allergy to:
any cyclin dependent kinase inhibitors
any of the other ingredients of KISQALI tablets (see list at the end of this leaflet).
Some of the symptoms of an allergic reaction may include:
Severe itching of the skin, with a red rash, or raised bumps;
Swelling of the face, lips, tongue, throat, or other parts of the body;
Difficulty in breathing or swallowing;
If you think you may be allergic, ask your doctor for advice.
If you experience an allergic reaction, stop using the medicine and inform your doctor
or pharmacist immediately.
Do not take KISQALI if you have:
A heart problem known as QT prolongation
This is caused by a change in the electrical activity of the heart, and is seen by
your doctor on an ECG (electrocardiogram), or
Conditions which put you at risk of getting QT prolongation
low potassium, magnesium, calcium or phosphorous levels in your blood
family history of QT prolongation, or
Taking other medicines which prolong the QT interval
Your doctor or pharmacist will know more about this.
Women of child-bearing age who recently became postmenopausal or peri menopausal should
not commence treatment with KISQALI until your post-menopausal status is fully established.
Do not take KISQALI if you are pregnant or breast feeding.
It may affect your baby if you take it while you are pregnant or breast feeding.
Do not take this medicine after the expiry date printed on the pack or if the packaging
is torn or shows signs of tampering.
The expiry date refers to the last day of that month.
If it has expired or is damaged, return it to your pharmacist for disposal.
If you are not sure whether you should start taking this medicine, talk to your doctor.
Before you start to take it
Tell your doctor if you are allergic to any other medicines, foods, dyes or preservatives.
Your doctor will want to know if you are prone to allergies.
Tell your doctor or pharmacist before taking KISQALI if you have any of the following
Fever, sore throat or mouth ulcers due to infections (signs of low level of white
Any problems with your liver or previously had any type of liver disease
Have or had heart failure, a heart attack, heart disorders or heart rhythm disorders,
such as an irregular heartbeat, including a condition called prolonged QT syndrome
(QT interval prolongation)
Low levels of potassium, magnesium, calcium, or phosphorous in your blood
Are still having periods
Are pregnant, think you may be pregnant, or plan to become pregnant
Plan to breast-feed
Are taking any medicines or supplements (see "Taking other medicines").
Taking other medicines
Before you take KISQALI, tell your doctor or pharmacist if you are taking or have
recently taken any other medicines, including medicines or supplements that you can
buy without a prescription from a pharmacy, supermarket or health food shop.
These may interact with KISQALI. In particular, some medicines used to treat:
Fungal infections, such as ketoconazole, itraconazole, voriconazole or posaconazole;
Certain types of bacterial infections, such as erythromycin, clarithromycin, azithromycin,
moxifloxacin, levofloxacin, norfloxacin, and ciprofloxacin
HIV/AIDS such as: ritonavir, saquinavir, idinavir, lopinavir, nelfinavir, telaprevir
Seizures or fits (anti-epileptics) such as carbamazepine, phenytoin, rifampin and
Heart rhythm problems such as amiodarone, disopyramide, procainamide, quinidine and
Depression, anxiety, sleep problems, or other conditions with a herbal product called
St John's Wort (also known as Hypericum perforatum).
Ask your doctor or pharmacist if you are not sure whether your medicine is one of
the medicines listed above.
Keep a list of the medicines you take, so you can show it to your doctor, nurse or
pharmacist when you get a new medicine.
Other medicines may be affected by KISQALI or they may affect how well KISQALI works.
This includes medicines or supplements obtained without a prescription and/or herbal
You should also tell your doctor if you are already taking KISQALI if you are prescribed
a new medicine that you have not taken previously during KISQALI treatment.
Your doctor or pharmacist can tell you what to do when taking KISQALI with other medicines.
Women of child-bearing potential
If you are pregnant or breast-feeding, think you might be pregnant, or are planning
to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
KISQALI may harm your unborn baby if you are pregnant. KISQALI may harm your baby
if you are breastfeeding. Your doctor will discuss with you the potential risks of
taking KISQALI during pregnancy or when breast feeding.
If until recently you still had menstrual periods, you should delay commencing KISQALI
until your post-menopausal status is determined.
If you are able to become pregnant, your doctor will discuss with you the potential
risks of taking KISQALI during pregnancy or breast-feeding.
Women who are able to become pregnant should have a negative pregnancy test result
before starting treatment and use effective birth control during treatment and for
at least 21 days after stopping KISQALI.
Men taking KISQALI
KISQALI may reduce fertility in male patients.
How to take KISQALI
KISQALI is taken in repeating cycles of 28 days (4 weeks).
KISQALI is taken each day for 21 days, followed by a treatment break of 7 days when
KISQALI tablets are not taken.
Always take KISQALI exactly as your doctor and pharmacist has told you.
Your doctor or pharmacist will tell you exactly how many tablets to take and which
days to take them on. These directions may differ from the information contained in
Check with your doctor or pharmacist if you are not sure.
Do not change the KISQALI dose or schedule without talking to your doctor.
If you do not understand the instructions on the pack, ask your doctor or pharmacist
How much KISQALI to take
DAYS 1 to 21 (of repeating 28 day cycles)
The usual starting dose of KISQALI is 600 mg (three KISQALI 200 mg tablets) once daily.
Your doctor will tell you exactly how many tablets of KISQALI to take.
Do not exceed the recommended dose prescribed by your doctor.
It is very important to follow your doctor’s recommendations. If you have certain
side effects, your doctor may ask you to change to a lower dose, or ask you to skip
the dose or to discontinue treatment.
DAYS 22 to 28 (of repeating 28 day cycles)
Do not take any KISQALI tablets this week.
It is very important that you do not take KISQALI during Week 4 of the cycle. That
is on DAYS 22 to 28 of every cycle.
The 7 day break when you do not take KISQALI tablets will help your body to recover
and decrease the risks of getting any potentially serious side effects or an infection.
When taking KISQALI and an aromatase inhibitor in combination, keep taking the aromatase
inhibitor ONLY on these 7 days, as directed by your doctor.
Resume taking Kisqali once a day on the following week.
If you are aged 65 years and over, you can use KISQALI at the same dose as for other
When to take it
Take KISQALI tablets at about the same time each day, preferably in the morning on
days 1 to 21 of a 28 day cycle.
Taking the tablets at the same time each day will have the best effect. It will also
help you remember when to take them.
KISQALI tablet packs have a fifth flap to help you keep track of your doses during
each treatment cycle.
Write in the days of the week starting with the first day of your treatment. Cross
off a circle after each tablet that you take, in each week of the cycle, as shown
in the pack example.
How to take it
Swallow KISQALI tablets whole with a glass of water or other liquid.
Do not chew, crush, or split the tablets prior to swallowing.
No tablet should be ingested if it is broken, cracked, or otherwise not intact.
Taking the aromatase inhibitor or fulvestrant in combination with KISQALI
These other medicines are supplied separately.
Your doctor will tell you the dose of the aromatase inhibitor or fulvestrant, or LHRH
agonist that you should take and when you should take it.
Keep taking theses medicines as directed by your doctor.
Taking with food or drinks
KISQALI tablets can be taken with or without food.
However, do not eat grapefruit (or drink grapefruit juice), pummelos, star-fruit,
or Seville oranges during your treatment with KISQALI.
It may change the way that KISQALI is absorbed in your body.
How long to take it
This is a long-term treatment, which may continue for many months or years.
Continue taking KISQALI once a day on days 1 to 21, of repeating 28 day cycles, for
as long as your doctor tells you to do so.
Your doctor will regularly check your condition to ensure that KISQALI treatment is
having the desired effect.
If you are unsure, talk to your doctor.
If you forget to take it
If you miss a dose of KISQALI on Days 1 to 21, skip the missed dose that day. Take
your next dose at your regular time on the following day.
Do not take a double dose to make up for a forgotten or a missed dose. Instead, wait
until it is time for your next dose and then take your usual dose.
If you are not sure what to do, ask your doctor or pharmacist.
If you have trouble remembering when to take or skip KISQALI, keep a treatment diary,
or ask your doctor, nurse or pharmacist for some hints.
If you take more KISQALI than you should (overdose)
If you think that you have accidentally taken too many tablets or that someone else
may have accidentally taken your medicine (or the aromatase inhibitor), immediately
telephone your doctor, a hospital, or the Poisons Information Centre (telephone 13
11 26) for advice. Go to Accident and Emergency at your nearest hospital. Take the
KISQALI pack with you.
Do this even if there are no signs of discomfort or poisoning.
You may need medical attention.
Keep the telephone numbers for these places handy.
While you are taking KISQALI
Things you must do
If you become pregnant while taking KISQALI, tell your doctor immediately.
You should not take this medicine while you are pregnant.
Follow your doctor's instructions carefully.
If you do not follow your doctor's instructions, your treatment may not help or you
may have unwanted side effects.
Be sure to keep all of your doctor's appointments so that your progress can be checked.
You will have regular blood tests before and during treatment with KISQALI to monitor
your liver function, the amount of blood cells, and electrolytes (blood salts including
potassium, calcium, magnesium and phosphate) in your body.
The electrical activity of your heart will also be checked before and during treatment
(with a test called an electrocardiogram or ECG). These tests can be affected by KISQALI.
If necessary, your doctor may decide to temporarily stop or reduce your KISQALI dose
to allow your liver function, blood cells, electrolytes or heart activity to recover.
Your doctor may also decide to stop treatment permanently.
If you are about to be started on any new medicine, remind your doctor and pharmacist
that you are taking KISQALI.
Tell any other doctor, dentist or pharmacist who treats you that you are taking KISQALI.
Be careful when driving or using machines during your treatment with KISQALI.
Treatment with KISQALI may lead to tiredness, dizziness or vertigo.
Things you must not do
Do not use KISQALI to treat any other complaints unless your doctor says you can.
Do not give this medicine to anyone else, even if their symptoms seem to be similar
Things to be careful of
When taking KISQALI with an aromatase inhibitor, do not skip the aromatase inhibitor
on any day. It must be taken EVERY day as directed in the 28 day cycle.
Like all medicines, KISQALI can cause unwanted side effects, in addition to its beneficial
effects. Sometimes they are serious, and you may need medical treatment.
The side effects that you might experience with KISQALI are different to what you
may have experienced in the past, while taking hormonal therapy only.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you
are taking KISQALI.
Do not be alarmed by this list of possible side effects.
You may not experience any of them.
Ask your doctor or pharmacist to answer any questions you may have.
SERIOUS SIDE EFFECTS
Stop taking KISQALI and tell your doctor immediately or go to Accident and Emergency
at your nearest hospital if you notice any of the following symptoms during treatment
Signs of an allergic reaction (as given on page 1);
Fever, sweats or chills, cough, flu like symptoms, weight loss, shortness of breath,
blood in your phlegm, sores on your body, warm or painful areas on your body, diarrhoea
or stomach pain, feeling very tired (these may be signs of infections).
Fever, sore throat or mouth ulcers due to infections;
Tiredness, itchy yellow skin or yellowing of the whites of your eyes, nausea or vomiting,
loss of appetite, pain in the upper right side of the belly (abdomen), dark or brown
urine, bleeding or bruising more easily than normal (these may be signs of a liver
Spontaneous bleeding or bruising
Sore throat or mouth ulcers with a single episode of fever greater than 38.3°C, or
above 38°C for more than one hour and/or with infection (febrile neutropenia)
Serious infections with increased heart rate, shortness of breath or rapid breathing,
fever and chills (these may be signs of a sepsis which is an infection in the blood
system which may be life threatening).
Chest pain or discomfort, changes in heart beat (fast or slow), palpitations, light
headedness, fainting, dizziness, lips turning blue colour, shortness of breath, swelling
(oedema) of your lower limbs or skin (these may be signs of heart problems).
VERY COMMON SIDE EFFECTS
Tiredness, fatigue, pale skin
Sore throat, runny nose, blocked nose, sneezing, feeling of pressure or pain in the
cheeks or forehead with or without fever, cough, hoarseness, weak voice or voice loss
(signs of a respiratory tract infection)
Painful and frequent urination (signs of a urinary tract infection)
Shortness of breath, difficulty breathing
Mouth sores or ulcers with gum inflammation
Abdominal (belly) pain
Hair loss or hair thinning
Swollen hands, ankles or feet
Dizziness or light headedness
Very common side effects that may show up in your test results
Low level of:
Types of white blood cells
Red blood cells
Calcium in the blood, which may sometimes lead to cramps
Phosphate in the blood
Sugar in the blood
Albumin in the blood.
High level of:
Some liver function blood test result(s)
COMMON SIDE EFFECTS
Abdominal pain, nausea, vomiting, diarrhoea, swelling or bloating of the abdomen and
feeling sick (signs of gastroenteritis, which is an inflammation of the stomach lining)
Spontaneous bleeding or bruising
Watering or tearing of eyes
Strange taste in the mouth
Upset stomach, indigestion, heartburn
Sensation of losing balance (vertigo)
Loss of skin colour in patches (vitiligo)
Sore throat (oropharyngeal pain).
Common side effects that may show up in your test results
Low level of potassium in the blood, which could lead to disturbances in heart rhythm
Change in the electrical activity of the heart.
Tell your doctor if you notice anything else that is making you unwell.
Other side effects not listed above may happen in some people.
After taking KISQALI
Keep this medicine where children cannot reach it.
A locked cupboard at least one-and-a-half metres above the ground is a good place
to store medicines.
Keep your tablets in the blister until it is time to take them.
Store the tablets in a cool dry place below 30°C.
Do not store KISQALI in the bathroom or any other place that is hot or steamy.
Do not leave the tablets in the car or on window sills.
Heat and dampness can destroy some medicines. KISQALI will keep well if it is cool
If your doctor tells you to stop taking KISQALI or the tablets have passed their use
by (expiry date), ask your pharmacist what to do with any that are left over.
Medicines should not be disposed of via wastewater or household waste.
What it looks like
KISQALI 200 mg
Kisqali film coated tablets are light greyish violet, unscored, round, curved with
bevelled edges, debossed with "RIC" on one side and "NVR" on the other side.
The tablets are supplied in packs containing either 63, 42, or 21 tablets. All packs
contain three blister strips in each carton.
This pack is intended for patients taking the ribociclib daily dose of 600 mg (as
three tablets) once daily for 3 weeks.
Each blister strip contains 21 tablets.
This pack is intended for patients taking a reduced ribociclib daily dose of 400 mg
(as two tablets) once daily for 3 weeks.
Each blister strip contains 14 tablets.
This pack is intended for patients taking the lowest ribociclib daily dose of 200
mg (one tablet once daily).
Each blister strip contains 7 tablets.
Each KISQALI film coated tablet contains 200 mg of ribociclib, as the active ingredient,
in the form of the succinate salt.
Each tablet also contains:
Magnesium stearate (vegetable source) (E572)
Microcrystalline cellulose (E460(i))
Colloidal silicon dioxide
Polyvinyl alcohol (partially hydrolysed) (E1203)
Titanium dioxide (E171)
Iron oxide black CI77499 (E172)
Iron oxide red CI77491 (E172)
Iron oxide yellow CI77492 (E172)
Purified talc (E553b)
Lecithin (soy) (E322)
Xanthan gum (E415).
KISQALI does not contain sucrose, lactose, gluten, tartrazine, azo dyes, or any animal
KISQALI is supplied in Australia by:
NOVARTIS Pharmaceuticals Australia Pty Limited
ABN 18 004 244 160
54 Waterloo Road
Macquarie Park NSW 2113
Telephone 1800 671 203 www.novartis.com.au
® = Registered trademark
Australian Registration Number
AUST R 280246
Date of preparation
This leaflet was prepared in July 2019
Internal document code
(kis070819c is based on PI kis070819i)